{"url_path":"/sec/nrix/8-k/2026-05-15/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1549595/0001549595-26-000028-index.html","accession_number":"0001549595-26-000028","cik":"0001549595","ticker":"NRIX","issuer_name":"Nurix Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1549595/0001549595-26-000028-index.html","primary_entity_key":"0001549595","primary_entity_name":"Nurix Therapeutics, Inc."},"word_count":404,"has_tables":true,"body_markdown":"Item 5.07    Submission of Matters to a Vote of Security Holders.\n\nOn May 15, 2026, Nurix Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders exclusively online via live webcast (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on three proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on March 27, 2026 (the “Proxy Statement”). There were 83,747,013 shares of common stock present at the Annual Meeting in person or by proxy, which represented approximately 80.98% of the voting power of the shares of common stock entitled to vote at the Annual Meeting and constituted a quorum for the transaction of business. Holders of the Company’s common stock were entitled to one vote for each share held as of the close of business on March 20, 2026.\n\nThe stockholders of the Company voted on the following proposals at the Annual Meeting:\n\n1. To elect three Class III directors, each of whom is currently serving on the Company’s Board of Directors (the “Board”), each to serve a three-year term expiring at the Company’s 2029 annual meeting of stockholders and until his successor has been elected and qualified, or until his earlier resignation or removal.\n\n2. To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending November 30, 2026.\n\n3. To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.\n\nThe final voting results for each of these proposals are detailed below.\n\nProposal 1. Election of Directors\n\nNomineeVotes ForVotes WithheldBroker Non-Votes\n\nArthur T. Sands, M.D., Ph.D.63,592,94816,334,5703,819,495\n\nRoger Dansey, M.D.79,607,489320,0293,819,495\n\nPaul M. Silva59,298,61220,628,9063,819,495\n\nEach of the three nominees for director was elected to serve until the Company’s 2029 annual meeting of stockholders and until his successor has been elected and qualified, or until his earlier resignation or removal.\n\nProposal 2. Ratification of Appointment of Independent Registered Public Accounting Firm\n\nVotes ForVotes AgainstAbstentionsBroker Non-Votes\n\n83,555,977166,39124,645—\n\nThe stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending November 30, 2026.\n\nProposal 3. Approval, on a Non-binding Advisory Basis, of the Compensation of the Company’s Named Executive Officers\n\nVotes ForVotes AgainstAbstentionsBroker Non-Votes\n\n72,458,9206,895,394573,2043,819,495\n\nThe stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers.\n\n2"}